Selegiline in Parkinson's disease

Acta Neurologica Scandinavica
H Teräväinen

Abstract

Twenty patients with Parkinson's disease were treated with the MAO-B inhibitor selegiline (l-deprenyl) and placebo without levodopa (L-dopa) in a randomized double-blind clinical cross-over study to analyze relative importances of dopamine (DA) synthesis and metabolism. The daily dose of selegiline was gradually increased to a maximum of 30 mg in all patients. The clinical neurological disability (Columbia score) was about 10% less on selegiline (30 mg/day) than on placebo. This difference was neither statistically nor clinically significant. The results are compatible with the possibility that treatment with selegiline without concomitant L-dopa does not significantly increase DA concentration which remains low and is determined mainly by tyrosine hydroxylase activity. At low DA levels the DA re-uptake mechanism recaptures most of the released DA and DA deamination is of minor significance. The pathway of DA oxidation becomes more important only at higher DA concentrations, accomplished by bypassing the rate limiting step of tyrosine hydroxylation using L-dopa.

References

Oct 15, 1977·Lancet·A J LeesM B Youdim
Jan 1, 1978·Journal of Neural Transmission·E CsandaA Csanaky
Jan 1, 1978·Journal of Neural Transmission·J Knoll
Jan 1, 1978·Journal of Neural Transmission·P RiedererD Seemann
Jan 1, 1978·Journal of Neural Transmission·M D Yahr
Jan 1, 1978·Journal of Neural Transmission·G M SternM Sandler
Jan 1, 1978·Journal of Neural Transmission·U K RinneV Sonninen
Jan 1, 1989·Acta Neurologica Scandinavica. Supplementum·P F Teychenne, S Parker
Jan 1, 1989·Acta Neurologica Scandinavica. Supplementum·M D YahrD Moros
Sep 1, 1985·Journal of Affective Disorders·C M PareV Glover
Feb 1, 1986·Italian Journal of Neurological Sciences·S RuggieriA Agnoli
Jan 1, 1987·Psychopharmacology·P N TariotR M Cohen
Feb 1, 1988·Clinical Neuropharmacology·L I GolbeR C Duvoisin
Jun 1, 1985·Acta Neurologica Scandinavica·P BrodersenA Stigård
Jun 1, 1985·Italian Journal of Neurological Sciences·P GiovanniniT Caraceni
Jan 1, 1985·Psychopharmacology·T SunderlandD L Murphy
Apr 1, 1967·The British Journal of Psychiatry : the Journal of Mental Science·B BlackwellD Taylor
May 1, 1967·Neurology·M M Hoehn, M D Yahr
Jan 1, 1981·Neurology·T EislerD B Calne
May 1, 1983·The British Journal of Psychiatry : the Journal of Mental Science·J Mendlewicz, M B Youdim
Jan 1, 1983·Acta Neurologica Scandinavica. Supplementum·G M SternM Sandler
Jan 1, 1983·Acta Neurologica Scandinavica. Supplementum·J Presthus, A Hajba
Jan 1, 1983·Acta Neurologica Scandinavica. Supplementum·L OrelandA Stenström
Jan 1, 1983·Acta Neurologica Scandinavica. Supplementum·U K Rinne
Nov 1, 1980·Journal of Neurology, Neurosurgery, and Psychiatry·M SchachterB Testa
Jan 1, 1981·Journal of Neural Transmission·M Koulu, R Lammintausta

❮ Previous
Next ❯

Citations

Jan 1, 1993·Journal of Neural Transmission. Parkinson's Disease and Dementia Section·E H HeinonenM Scheinin
Nov 1, 2003·Archives of Clinical Neuropsychology : the Official Journal of the National Academy of Neuropsychologists·R A Stein, T L Strickland
Jul 2, 2008·Parkinsonism & Related Disorders·P FoleyP Riederer
Jul 1, 1997·Journal of Clinical Pharmacology·E H HeinonenR A Lammintausta
Jan 1, 1991·Acta Neurologica Scandinavica. Supplementum·H AllainH C Neukirch
Jan 1, 1991·Acta Neurologica Scandinavica. Supplementum·E H Heinonen, R Lammintausta
Jan 1, 1991·Acta Neurologica Scandinavica. Supplementum·U K Rinne
Dec 1, 1994·General Pharmacology·P H Yu
Sep 1, 1992·The International Journal of Neuroscience·R Sandyk
Nov 3, 1998·Clinical Pharmacology and Therapeutics·H ScheininL Bertilsson
Sep 17, 2009·Applied Microbiology and Biotechnology·Martin SakerVitor Manuel Vasconcelos
Feb 1, 1991·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·J D Grimes
Jun 1, 1991·Acta Neurologica Scandinavica·G NappiI Runge
May 11, 1992·Annals of the New York Academy of Sciences·I Shoulson
Jan 3, 2013·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·J J FerreiraW H Oertel
Feb 1, 1991·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·J C Furtado, M F Mazurek
Jan 1, 1995·Journal of Neural Transmission. General Section·A Fredriksson, T Archer
Jan 21, 1993·The New England Journal of Medicine·UNKNOWN Parkinson Study Group
Oct 14, 2006·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·M HorstinkUNKNOWN Movement Disorder Society-European Section
Oct 22, 2008·Expert Opinion on Pharmacotherapy·Matthias Löhle, Alexander Storch

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

© 2021 Meta ULC. All rights reserved